Trial intelligence / Profile preview

MOTION: Phase 3 study of vimseltinib versus placebo in tenosynovial giant cell tumor

2024-513624-42-00Phase 3Authorised

Sponsor

Deciphera Pharmaceuticals

Start

Dec 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

13